Qsymia vs. Wegovy: The Best Non-GLP-1 Medication Meets the Gold Standard

Qsymia is the strongest non-GLP-1 oral weight loss medication at 7–10% body weight loss. Wegovy now comes in pill form too. With generic Qsymia dropping to $50–$100/month, these two have never been closer on price — but they remain far apart on results.

For years, Qsymia was the forgotten middle child of weight loss medications — more effective than phentermine alone but overshadowed by the GLP-1 revolution. Then two things happened in quick succession: generic Qsymia launched in May 2025 at dramatically lower prices, and the Wegovy pill arrived in January 2026, creating the first direct oral-vs-oral comparison between these two classes.

That makes this comparison newly relevant for millions of patients.

What Qsymia Actually Is

Qsymia combines two existing drugs: low-dose phentermine (appetite suppression through stimulation) and extended-release topiramate (an anti-seizure medication that independently reduces appetite and food cravings). The combination is more effective than either drug alone.

At the highest dose (15mg phentermine / 92mg topiramate), clinical trials showed 10.9% average body weight loss at one year — substantially better than phentermine alone (5–7%) and the best result of any non-GLP-1 oral medication.

The generic launch in May 2025 was significant. Brand-name Qsymia cost $200+/month. Generic versions run $50–$100/month, making it suddenly competitive with compounded GLP-1 options on price.

Head-to-Head: The Numbers

The Teratogenicity Issue

This is the single most important safety distinction. Topiramate is a known teratogen — it causes birth defects, including cleft lip and palate, at rates 2–5 times higher than baseline. The FDA requires a negative pregnancy test before starting Qsymia and monthly tests during treatment. Women must use effective contraception.

GLP-1 medications are also contraindicated during pregnancy, but they don't cause birth defects — the recommendation is simply to stop 2 months before conception to allow the drug to clear. The risk profile is fundamentally different.

For any woman who might become pregnant — planned or unplanned — GLP-1 medications are the safer choice. This isn't a marginal consideration; it's a hard safety distinction.

The Cognitive Side Effects

Topiramate causes dose-dependent cognitive effects that patients describe as "brain fog" — difficulty finding words, slower processing speed, reduced concentration, and memory issues. These affect approximately 15–20% of patients and are the most common reason for discontinuation.

For professionals, students, or anyone whose work requires sharp cognitive performance, this side effect can be a dealbreaker. GLP-1 medications don't impair cognition.

When Qsymia Makes Sense

Budget is the priority: At $50–$100/month for generic, Qsymia costs 50–75% less than most GLP-1 options. For patients without insurance coverage for weight loss medication, the savings are substantial.

You want oral-only treatment: Before the Wegovy pill, Qsymia was the most effective oral option by a wide margin. Now it competes with oral semaglutide, but at half the price.

You tolerate topiramate well: Some patients experience no cognitive effects and find Qsymia highly effective. If you're one of them, the cost savings over GLP-1s are meaningful.

Not at risk of pregnancy: Men, post-menopausal women, and women using highly reliable contraception (IUD, implant, sterilization) can consider Qsymia without the teratogenicity concern.

When Wegovy Is the Better Choice

Maximum effectiveness matters: At 15–17% vs 7–10%, the Wegovy injection nearly doubles Qsymia's weight loss. The oral pill (~15%) still outperforms by roughly 50%.

Pregnancy is possible: Even with contraception, unplanned pregnancies occur. GLP-1 medications have a safer risk profile.

Cognitive performance matters: No brain fog, no word-finding difficulties, no processing speed changes.

Cardiovascular protection: The SELECT trial data showing 20% MACE reduction with semaglutide has no equivalent for Qsymia.

The Bottom Line

Generic Qsymia has carved out a legitimate niche: the most effective budget oral option for weight loss. At $50–$100/month, it delivers 7–10% body weight loss that genuinely changes health outcomes for many patients.

But the Wegovy pill has made the competitive landscape harder for Qsymia. For $50–$150 more per month, patients get 50–100% more weight loss without cognitive side effects or teratogenicity concerns. For most patients who can afford the difference, GLP-1 medications remain the better value on a cost-per-result basis.

The exception: cost-sensitive patients who need an oral medication and aren't at risk of pregnancy. For them, generic Qsymia is a strong option worth discussing with their provider.